Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Early and sustained palliative care intervention is not superior to on-demand palliative care referral for patients with high-risk leukemias or myelodysplastic syndrome

Gordon Smilnak, Amelia Hodson, David Brighton, Katherine Murphy, Cara Hanby, Morgan Van Ornum, Gina Petroni, Leslie Blackhall, Karen Ballen, Firas El Chaer

Blood (2025) 146 (Supplement 1): 961.

https://doi.org/10.1182/blood-2025-961

Published: 2025

Journal Articles

Area deprivation index as a predictor of survival and treatment disparities in older adults with Acute Myeloid Leukemia: A population-based Study

Valerie Tran, Gloribel Bonilla, Caroline Mulligan, Qingyi He, Asal Pilehvari, Wen You, Charbel El Chaer, Nadia Bambace, Talia Zahra, Lyle Feinstein, Ariel Perez Perez, Daniel Reed, Firas El Chaer

Blood (2025) 146 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2025-2847

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Clia plus venetoclax for AML: Feasibility and efficacy in a hybrid community setting

Nadia Bambace, Ethan Eilo, Tiba Al Sagheer, Audra Andersen, Firas El Chaer, Lyle Feinstein, Eduardo Guizan Corrales, Ariel Perez Perez, Alga Ramos Morales, Moe Shwin, Jessica Unzaga, Talia Zahra

Blood (2025) 146 (Supplement 1): 6962.

https://doi.org/10.1182/blood-2025-6962

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

Blood (2025) 146 (4): 437–455.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

Natalie Pham, Jeffrey Lantz, Jr., Caroline Jones, Debamita Kundu, Nicholas McCann, Firas El Chaer, Daniel Reed, Michael Keng

Blood (2024) 144 (Supplement 1): 791.

https://doi.org/10.1182/blood-2024-211962

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

Impact of Social Determinants of Health and Geographic Location on Real-World Outcomes in AML Patients Undergoing Low-Intensity Chemotherapy

Valerie Tran, Gordon Smilnak, Nandan Srinivasa, Firas El Chaer, Michael Keng, Daniel Reed

Blood (2024) 144 (Supplement 1): 7904.

https://doi.org/10.1182/blood-2024-201720

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2023-186376

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Blood (2023) 142 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2023-180121

Published: 2023

Journal Articles

Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

Jeffrey Lantz, Jr., Natalie Pham, Caroline Jones, Debamita Kundu, Nicholas McCann, Firas El Chaer, Daniel Reed, Michael Keng

Blood (2023) 142 (Supplement 1): 7436.

https://doi.org/10.1182/blood-2023-190176

Published: 2023

Journal Articles

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Tsewang Tashi, Firas El Chaer, Victor Priego, Oleh Zagrijtschuk, Albert Qin, Jewell Jessup, Craig Zimmerman, Ray Urbanski, Lucia Masarova

Blood (2023) 142 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2023-189912

Published: 2023

Journal Articles

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2023-178839

Published: 2023

Journal Articles

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 424.

https://doi.org/10.1182/blood-2023-186822

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early and sustained palliative care intervention is not superior to on-demand palliative care referral for patients with high-risk leukemias or myelodysplastic syndrome

Area deprivation index as a predictor of survival and treatment disparities in older adults with Acute Myeloid Leukemia: A population-based Study

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Clia plus venetoclax for AML: Feasibility and efficacy in a hybrid community setting

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Impact of Social Determinants of Health and Geographic Location on Real-World Outcomes in AML Patients Undergoing Low-Intensity Chemotherapy

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only